# Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors

> **NCT07505069** · EARLY_PHASE1 · RECRUITING · sponsor: **Nanolattix Biotechnology Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RT01-89Zr

## Key facts

- **NCT ID:** NCT07505069
- **Lead sponsor:** Nanolattix Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-02-28
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07505069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07505069, "Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07505069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*